AQST Valuation

Aquestive Therapeutics Inc

Add to Watchlist

Advanced Chart

6.820

+0.16(2.402%)1D

AQST Relative Valuation

AQST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AQST is overvalued; if below, it's undervalued.

Historical Valuation

Aquestive Therapeutics Inc (AQST) is now in the Fair zone, suggesting that its current forward PS ratio of 6.82 is considered Fairly compared with the five-year average of -4.42. The fair price of Aquestive Therapeutics Inc (AQST) is between 3.02 to 7.18 according to relative valuation methord.

Relative Value

Fair Zone

3.02-7.18

Current Price：6.82

Fair

-10.97

Trailing

Forward

-14.33

EV/EBITDA

Aquestive Therapeutics Inc. (AQST) has a current EV/EBITDA of -14.33. The 5-year average EV/EBITDA is -6.35. The thresholds are as follows: Strongly Undervalued below -13.51, Undervalued between -13.51 and -9.93, Fairly Valued between -2.76 and -9.93, Overvalued between -2.76 and 0.82, and Strongly Overvalued above 0.82. The current Forward EV/EBITDA of -14.33 falls within the Strongly Undervalued range.

-15.22

EV/EBIT

Aquestive Therapeutics Inc. (AQST) has a current EV/EBIT of -15.22. The 5-year average EV/EBIT is -5.52. The thresholds are as follows: Strongly Undervalued below -11.41, Undervalued between -11.41 and -8.47, Fairly Valued between -2.58 and -8.47, Overvalued between -2.58 and 0.36, and Strongly Overvalued above 0.36. The current Forward EV/EBIT of -15.22 falls within the Strongly Undervalued range.

6.82

Aquestive Therapeutics Inc. (AQST) has a current PS of 6.82. The 5-year average PS is 4.01. The thresholds are as follows: Strongly Undervalued below -1.18, Undervalued between -1.18 and 1.42, Fairly Valued between 6.61 and 1.42, Overvalued between 6.61 and 9.21, and Strongly Overvalued above 9.21. The current Forward PS of 6.82 falls within the Overvalued range.

-17.11

P/OCF

Aquestive Therapeutics Inc. (AQST) has a current P/OCF of -17.11. The 5-year average P/OCF is -4.70. The thresholds are as follows: Strongly Undervalued below -12.81, Undervalued between -12.81 and -8.75, Fairly Valued between -0.65 and -8.75, Overvalued between -0.65 and 3.40, and Strongly Overvalued above 3.40. The current Forward P/OCF of -17.11 falls within the Strongly Undervalued range.

-21.01

P/FCF

Aquestive Therapeutics Inc. (AQST) has a current P/FCF of -21.01. The 5-year average P/FCF is -7.94. The thresholds are as follows: Strongly Undervalued below -21.51, Undervalued between -21.51 and -14.72, Fairly Valued between -1.15 and -14.72, Overvalued between -1.15 and 5.64, and Strongly Overvalued above 5.64. The current Forward P/FCF of -21.01 falls within the Undervalued range.

Aquestive Therapeutics Inc (AQST) has a current Price-to-Book (P/B) ratio of -9.33. Compared to its 3-year average P/B ratio of -4.49 , the current P/B ratio is approximately 107.97% higher. Relative to its 5-year average P/B ratio of -3.66, the current P/B ratio is about 155.14% higher. Aquestive Therapeutics Inc (AQST) has a Forward Free Cash Flow (FCF) yield of approximately -6.06%. Compared to its 3-year average FCF yield of -8.14%, the current FCF yield is approximately -25.52% lower. Relative to its 5-year average FCF yield of -20.32% , the current FCF yield is about -70.16% lower.

-9.33

P/B

Median3y

-4.49

Median5y

-3.66

-6.06

FCF Yield

Median3y

-8.14

Median5y

-20.32

Competitors Valuation Multiple

The average P/S ratio for AQST's competitors is 8.21, providing a benchmark for relative valuation. Aquestive Therapeutics Inc Corp (AQST) exhibits a P/S ratio of 6.82, which is -16.95% above the industry average. Given its robust revenue growth of -50.23%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AQST.O

Aquestive Therapeutics Inc

EyePoint Pharmaceuticals Inc

Arbutus Biopharma Corp

Akebia Therapeutics Inc

Performance Decomposition

Market capitalization of AQST increased by 33.99% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -13.66 to -135.44.

The secondary factor is the Revenue Growth, contributed -50.23%to the performance.

Overall, the performance of AQST in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-50.23%

20.10M → 10.00M

Revenue Growth

891.51%

-13.66 → -135.44

Margin Expansion

-807.29%

1.40 → -9.89

P/E Change

33.99%